Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
QTTB Stock Forecast 2025-2026
$1.77
Current Price
$21.22M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to QTTB Price Targets
+1,029.9%
To High Target of $20.00
+465.0%
To Median Target of $10.00
+239.0%
To Low Target of $6.00
QTTB Price Momentum
+14.2%
1 Week Change
-16.5%
1 Month Change
-94.2%
1 Year Change
-48.5%
Year-to-Date Change
-96.7%
From 52W High of $53.79
+28.3%
From 52W Low of $1.38
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching (QTTB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on QTTB and similar high-potential opportunities.
Latest QTTB Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, QTTB has a neutral consensus with a median price target of $10.00 (ranging from $6.00 to $20.00). The overall analyst rating is Buy (7.3/10). Currently trading at $1.77, the median forecast implies a 465.0% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jay Olson at Oppenheimer, projecting a 1,029.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
QTTB Analyst Ratings
1
Buy
2
Hold
0
Sell
QTTB Price Target Range
Low
$6.00
Average
$10.00
High
$20.00
Current: $1.77
Latest QTTB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for QTTB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $15.00 |
| Feb 11, 2025 | Piper Sandler | Christopher Raymond | Neutral | Downgrade | $4.00 |
| Feb 11, 2025 | BMO Capital | Etzer Darout | Market Perform | Downgrade | $3.00 |
| Dec 12, 2024 | BMO Capital | Etzer Darout | Outperform | Maintains | $22.00 |
| Dec 12, 2024 | Guggenheim | Yatin Suneja | Neutral | Downgrade | $0.00 |
| Dec 11, 2024 | Oppenheimer | Jay Olson | Outperform | Maintains | $20.00 |
| Dec 11, 2024 | Leerink Partners | Thomas Smith | Market Perform | Downgrade | $9.00 |
| Dec 11, 2024 | Piper Sandler | Christopher Raymond | Overweight | Maintains | $20.00 |
| Dec 11, 2024 | Raymond James | Steven Seedhouse | Outperform | Downgrade | $22.00 |
| Dec 11, 2024 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $16.00 |
| Dec 6, 2024 | BMO Capital | Etzer Darout | Outperform | Initiates | $64.00 |
| Oct 24, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Initiates | $90.00 |
| Sep 11, 2024 | Wells Fargo | Sarah Akers | Overweight | Initiates | $95.00 |
| Jun 17, 2024 | Guggenheim | Yatin Suneja | Buy | Initiates | $100.00 |
| May 21, 2024 | Leerink Partners | Thomas Smith | Outperform | Initiates | $54.00 |
| Apr 11, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $50.00 |
| Apr 2, 2024 | Piper Sandler | Christopher Raymond | Overweight | Initiates | $45.00 |
Q32 Bio Inc. (QTTB) Competitors
The following stocks are similar to based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Q32 Bio Inc. (QTTB) Financial Data
Q32 Bio Inc. has a market capitalization of $21.22M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -267.2%.
Valuation Metrics
Market Cap
$21.22M
Enterprise Value
$-25,460,150
P/E Ratio
0.0x
PEG Ratio
-0.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+303.3%
Current Ratio
4.7x
Debt/Equity
3.3x
ROE
-267.2%
ROA
-33.8%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Q32 Bio Inc. (QTTB) Business Model
About Q32 Bio Inc.
What They Do
Develops treatments for immune-mediated diseases.
Business Model
The company focuses on addressing unmet medical needs in autoimmune and inflammatory diseases through the development of targeted therapeutics, including biologics and small molecules. It generates revenue by advancing its innovative treatment pipeline aimed at improving patient outcomes and quality of life.
Additional Information
Q32 Bio operates within the biopharmaceutical sector, particularly in fields like dermatology, rheumatology, and gastroenterology. The company is positioned as a key player in the biotech industry, emphasizing precision medicine and innovative therapeutic strategies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
42
CEO
Ms. Jodie Pope Morrison
Country
United States
IPO Year
N/A
Website
www.q32bio.comQ32 Bio Inc. (QTTB) Latest News & Analysis
Latest News
Quick Summary
Q32 Bio Inc. has dosed its first patient in the SIGNAL-AA Phase 2a Part B trial, with results expected in 1H'26. The company holds $65.5 million in cash, funding operations into 2H'26.
Why It Matters
Q32 Bio's advancements in clinical trials and Fast Track designation for bempikibart signal potential market approval, while strong cash reserves ensure operational stability through 2026.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio Inc. received FDA Fast Track designation for its drug bempikibart (ADX-914) aimed at treating alopecia areata, potentially accelerating its development and approval process.
Why It Matters
Q32 Bio's Fast Track designation for bempikibart accelerates its development and approval process, potentially increasing market competitiveness and investor interest in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio Inc. has initiated dosing for the first patients in Part A and Part B of its SIGNAL-AA Phase 2a trial for bempikibart in alopecia areata, with topline data expected in 1H'26.
Why It Matters
The timely progress of Q32 Bio's clinical trial could influence stock performance, as successful results may lead to increased investor confidence and potential market opportunities.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio (QTTB) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may drive the stock higher.
Why It Matters
Q32 Bio's upgrade to Zacks Rank #2 signals increased investor confidence in its earnings potential, likely leading to higher stock demand and price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Q32 Bio presented positive Phase 2a data for bempikibart in alopecia areata at the AAD meeting. The company has $78M in cash, funding operations into 2H'26.
Why It Matters
The positive Phase 2a results for bempikibart in treating alopecia areata could signal a promising new treatment, potentially boosting Q32 Bio's market position and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Q32 Bio's bempikibart shows promising SALT reduction in severe alopecia areata patients, with ongoing effects post-treatment. Phase 2a trial indicates safety; further studies planned for 2025.
Why It Matters
Positive results for bempikibart in treating alopecia areata suggest potential for a new therapy, boosting Q32 Bio's prospects and likely attracting investor interest in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About QTTB Stock
What is Q32 Bio Inc.'s (QTTB) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Q32 Bio Inc. (QTTB) has a median price target of $10.00. The highest price target is $20.00 and the lowest is $6.00.
Is QTTB stock a good investment in 2025?
According to current analyst ratings, QTTB has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for QTTB stock?
Wall Street analysts predict QTTB stock could reach $10.00 in the next 12 months. This represents a 465.0% increase from the current price of $1.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Q32 Bio Inc.'s business model?
The company focuses on addressing unmet medical needs in autoimmune and inflammatory diseases through the development of targeted therapeutics, including biologics and small molecules. It generates revenue by advancing its innovative treatment pipeline aimed at improving patient outcomes and quality of life.
What is the highest forecasted price for QTTB Q32 Bio Inc.?
The highest price target for QTTB is $20.00 from Jay Olson at Oppenheimer, which represents a 1,029.9% increase from the current price of $1.77.
What is the lowest forecasted price for QTTB Q32 Bio Inc.?
The lowest price target for QTTB is $6.00 from at , which represents a 239.0% increase from the current price of $1.77.
What is the overall QTTB consensus from analysts for Q32 Bio Inc.?
The overall analyst consensus for QTTB is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are QTTB stock price projections?
Stock price projections, including those for Q32 Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 18, 2025 1:28 AM UTC